Oluyemi Okupe Sells 142,886 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 142,886 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.93, for a total transaction of $4,276,577.98. Following the completion of the transaction, the chief financial officer now directly owns 112,186 shares in the company, valued at approximately $3,357,726.98. This represents a 56.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, October 14th, Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09.
• On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.96, for a total value of $196,965.28.
• On Friday, September 20th, Oluyemi Okupe sold 12,651 shares of Hims & Hers Health stock. The stock was sold at an average price of $16.79, for a total value of $212,410.29.
• On Tuesday, September 3rd, Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40.

Hims & Hers Health Trading Down 7.3 %

Shares of Hims & Hers Health stock opened at $19.32 on Friday. The firm has a market capitalization of $4.15 billion, a PE ratio of 43.91 and a beta of 1.06. The firm’s 50 day moving average is $19.76 and its 200 day moving average is $18.87. Hims & Hers Health, Inc. has a 1 year low of $7.40 and a 1 year high of $30.44.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same period in the prior year, the business earned ($0.04) earnings per share. The company’s revenue for the quarter was up 77.1% compared to the same quarter last year. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on HIMS shares. Piper Sandler restated a “neutral” rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. TD Cowen raised their price objective on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group boosted their price target on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $20.71.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently made changes to their positions in HIMS. Geode Capital Management LLC raised its holdings in Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after buying an additional 482,177 shares during the last quarter. Barclays PLC raised its stake in shares of Hims & Hers Health by 9.7% during the third quarter. Barclays PLC now owns 308,363 shares of the company’s stock valued at $5,680,000 after acquiring an additional 27,231 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its holdings in shares of Hims & Hers Health by 312.6% during the third quarter. Y Intercept Hong Kong Ltd now owns 134,018 shares of the company’s stock worth $2,469,000 after purchasing an additional 101,536 shares during the period. MML Investors Services LLC bought a new stake in shares of Hims & Hers Health in the third quarter worth $197,000. Finally, Main Management ETF Advisors LLC acquired a new stake in Hims & Hers Health in the third quarter valued at $672,000. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.